Ruboxistaurin

Ruboxistaurin

Systematic (IUPAC) name
(9S)-9-[(dimethylamino)methyl]-6,7,10,11-tetrahydro-9H,18H-5,21:12,17-di(metheno)dibenzo[e,k]pyrrolo[3,4-h][1,4,13]oxadiazacyclohexadecine-18,20-dione
Identifiers
CAS Number	169939-94-0
ATC code	None
PubChem	CID 153999
IUPHAR/BPS	5263
ChemSpider	135727
UNII	721809WQCP
ChEMBL	CHEMBL91829
Chemical data
Formula	C28H28N4O3
Molar mass	468.546 g/mol
InChI InChI=1S/C28H28N4O3/c1-30(2)15-18-11-12-31-16-21(19-7-3-5-9-23(19)31)25-26(28(34)29-27(25)33)22-17-32(13-14-35-18)24-10-6-4-8-20(22)24/h3-10,16-18H,11-15H2,1-2H3,(H,29,33,34)/t18-/m0/s1 Key:ZCBUQCWBWNUWSU-SFHVURJKSA-N
(what is this?)  (verify)

Ruboxistaurin (proposed brand name Arxxant) is an investigational drug for diabetic peripheral retinopathy being investigated by Eli Lilly and Company. It is a member of the bisindolylmaleimide family.

On February 2006, Lilly submitted a New Drug Application for ruboxistaurin, and on August 18, 2006, Lilly received an "approvable" letter from the United States Food and Drug Administration for ruboxistaurin,^[1] with a request for an additional clinical trial, which would take 5 years to complete.^[2]

Mechanism of action

Ruboxistaurin is an inhibitor of protein kinase C-beta.^[3]

References

1. "Drugs.com, Eli Lilly and Company Announces Approvable Letter Issued by FDA for Arxxant". Retrieved 2008-02-15.
2. "Drugs.com, Lilly Announces FDA Requirement of Additional Clinical Trial Before Ruboxistaurin Could Be Approved for Treatment of Diabetic Retinopathy". Retrieved 2008-02-15.
3. Clarke M, Dodson PM (December 2007). "PKC inhibition and diabetic microvascular complications". Best Pract Res Clin Endocrinol Metab 21 (4): 573–86. doi:10.1016/j.beem.2007.09.007. PMID 18054736.

External links

• Eli Lilly and Company Product Pipeline